Intercept Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Intercept Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 22.4%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento anual de 17.7%. Los ingresos han ido creciendo a una tasa media de 8.3% al año.

Información clave

22.4%

Tasa de crecimiento de los beneficios

26.2%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	-14.6%
Tasa de crecimiento de los ingresos	8.3%
Rentabilidad financiera	-80.0%
Margen neto	-18.1%
Última actualización de beneficios	30 Sep 2023

Actualizaciones de resultados anteriores recientes

Recent updates

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Intercept Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

DB:I4P Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Sep 23	318	-57	212	160
30 Jun 23	306	-159	210	163
31 Mar 23	295	-173	196	171
31 Dec 22	286	-175	176	177
30 Sep 22	277	-202	168	187
30 Jun 22	266	-115	166	187
31 Mar 22	263	-120	170	180
31 Dec 21	261	-136	177	183
30 Sep 21	275	-144	200	185
30 Jun 21	288	-193	230	189
31 Mar 21	297	-231	279	185
31 Dec 20	234	-273	261	189
30 Sep 20	301	-321	356	204
30 Jun 20	283	-339	362	216
31 Mar 20	272	-347	339	241
31 Dec 19	252	-345	317	243
30 Sep 19	234	-335	295	241
30 Jun 19	219	-314	275	229
31 Mar 19	196	-318	270	217
31 Dec 18	180	-309	255	207
30 Sep 18	164	-333	265	200
30 Jun 18	159	-341	269	198
31 Mar 18	146	-352	271	195
31 Dec 17	131	-360	270	190
30 Sep 17	107	-369	268	186
30 Jun 17	71	-385	261	175
31 Mar 17	46	-376	239	166
31 Dec 16	25	-413	229	154
30 Sep 16	12	-381	210	131
30 Jun 16	7	-343	181	123
31 Mar 16	2	-314	157	117
31 Dec 15	3	-226	119	113
30 Sep 15	3	-173	71	107
30 Jun 15	3	-158	55	107
31 Mar 15	3	-77	42	94
31 Dec 14	2	-283	35	80
30 Sep 14	2	-261	27	66
30 Jun 14	2	-257	21	47
31 Mar 14	2	-304	16	37
31 Dec 13	2	-68	13	28
30 Sep 13	2	-86	11	23
30 Jun 13	2	-61	8	18
31 Mar 13	2	-53	7	18
31 Dec 12	2	-46	5	16

Ingresos de calidad: I4P actualmente no es rentable.

Margen de beneficios creciente: I4P actualmente no es rentable.

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: I4P no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 22.4% por año.

Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de I4P en el último año con su promedio de 5 años, ya que actualmente no es rentable.

Beneficios vs. Industria: I4P no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Biotechs (-14.4%).

Rentabilidad financiera

Alta ROE: I4P tiene una rentabilidad financiera negativa (-79.99%), ya que actualmente no es rentable.

Intercept Pharmaceuticals Resultados de beneficios anteriores

Pasado controles de criterios 0/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2023 earnings released: US$0.066 loss per share (vs US$3.04 loss in 3Q 2022)

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.68 loss in 2Q 2022)

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

First quarter 2023 earnings released: US$0.77 loss per share (vs US$1.13 loss in 1Q 2022)

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Recent updates

Intercept Pharmaceuticals, Inc. Files Form 15

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Announces New Phase 2 Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Key Biomarkers of PBC-Induced Liver Damage At AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals, Inc. Announces New Findings from Long-Term Extension of Landmark POISE Trial in PBC Showing Importance of Biomarkers Beyond ALP at AASLD the Liver Meeting® 2023

Intercept Pharmaceuticals' Common Stock Ceased to be Traded on the NASDAQ Stock Market

Alfasigma S.p.A. completed the acquisition of Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT).

Third quarter 2023 earnings released: US$0.066 loss per share (vs US$3.04 loss in 3Q 2022)

Persephone Biosciences Appoints Daniel Bradbury as Chair of the Board of Directors

Alfasigma S.p.A. entered into a definitive merger agreement to acquire Intercept Pharmaceuticals, Inc. (NasdaqGS:ICPT) for approximately $840 million.

Now 22% undervalued after recent price drop

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.68 loss in 2Q 2022)

Intercept Pharmaceuticals Provides Net Sales Guidance for the Full Year of 2023

Intercept Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Intercept Pharmaceuticals, Inc. Presents New Data Showing Significant Impact of OCA-Bezafibrate Combination on Normalization of Multiple Biomarkers of PBC-Induced Liver Damage

Intercept Pharmaceuticals, Inc. Announces New Data Showing Potential of Fixed-Dose Combination of OCA and Bezafibrate to Normalize Multiple Biomarkers in PBC to be Featured in Podium Presentation at EASL Congress 2023

Forecast breakeven date moved forward to 2024

First quarter 2023 earnings released: US$0.77 loss per share (vs US$1.13 loss in 1Q 2022)

Full year 2022 earnings released: US$5.17 loss per share (vs US$2.87 loss in FY 2021)

U.S. Food and Drug Administration Accepts Intercept Pharmaceuticals, Inc.'s New Drug Application for OCA for the Treatment of Pre-Cirrhotic Liver Fibrosis Due to Nash

Forecast breakeven date pushed back to 2025

Intercept Pharmaceuticals, Inc. Resubmits New Drug Application to U.S. Fda for Obeticholic Acid in Patients with Liver Fibrosis Due to NASH

Intercept Announces Development Program for Next-Generation FXR Agonist INT-787 in Severe Alcohol-Associated Hepatitis

Intercept Announces Two Analyses Demonstrating Improvement in Outcomes, Including Transplant-Free Survival, for PBC Patients Treated with OCA to be Presented at AASLD The Liver Meeting® 2022

Third quarter 2022 earnings released: US$3.04 loss per share (vs US$0.11 loss in 3Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 01, 2022

Intercept Pharmaceuticals Announces REVERSE Phase 3 Study of Obeticholic Acid in Compensated Cirrhosis Due to Nash Did Not Meet Its Primary Endpoint

Intercept Pharmaceuticals, Inc. Announces Improved Transplant-Free Survival Observed with Obeticholic Acid in People with PBC Published in Gastroenterology

Second quarter 2022 earnings released: US$0.68 loss per share (vs US$0.33 loss in 2Q 2021)

Intercept Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Intercept Pharmaceuticals, Inc. Announces Resignation of Bryan Ball as Chief Quality Officer and Senior Vice President of Operations, Effective August 12, 2022

Forecast to breakeven in 2022

Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid (OCA)

Intercept Pharmaceuticals, Inc. Provides Update on Nash Regulatory Timeline

Intercept Pharmaceuticals, Inc. Announces Resignation of Gail Cawkwell as Senior Vice President, Medical Affairs, Safety & Pharmacovigilance

Forecast to breakeven in 2024

Intercept Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study of OCA and Bezafibrate for the Treatment of Primary Biliary Cholangitis

Forecast breakeven date moved forward to 2022

First quarter 2022 earnings released: US$0.58 loss per share (vs US$1.22 loss in 1Q 2021)

Intercept Pharmaceuticals, Inc., Annual General Meeting, May 25, 2022

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2022

Intercept Pharmaceuticals, Inc. to Report Q4, 2021 Results on Mar 02, 2022

Pomerantz Law Firm Announces the Filing of A Class Action Against Intercept Pharmaceuticals, Inc

Forecast to breakeven in 2024

Intercept Pharmaceuticals Provides Update on Phase 3 REVERSE Trial in Compensated Cirrhosis Due to NASH

Intercept Pharmaceuticals, Inc. Announces Withdrawal of EMA Marketing Authorization Application for Obeticholic Acid for Advanced Liver Fibrosis Due to NASH

Third quarter 2021 earnings released: US$0.11 loss per share (vs US$2.02 loss in 3Q 2020)

Intercept Pharmaceuticals, Inc. announced a financing transaction

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$1.92 loss in 2Q 2020)

Intercept Pharmaceuticals, Inc. to Present New NASH and PBC Data at the Digital International Liver Congress™ 2021

Independent Director Daniel Welch has left the company

Intercept Pharmaceuticals, Inc. Provides Sales Guidance for the Fiscal Year 2021

First quarter 2021 earnings released: US$1.22 loss per share (vs US$2.86 loss in 1Q 2020)

CFO, Treasurer & Principal Accounting Officer has left the company

Intercept Pharmaceuticals, Inc. Appoints Rocco Venezia as Chief Accounting Officer

Chief Medical Officer has left the company

New 90-day low: €19.65

Full year 2020 earnings released: US$8.34 loss per share (vs US$10.89 loss in FY 2019)

Revenue misses expectations

Intercept Pharmaceuticals, Inc. Appoints Dagmar Rosa-Bjorkeson to its Board of Directors

Intercept Pharmaceuticals, Inc. Announces Management Changes

Intercept Pharmaceuticals, Inc. to Report Q4, 2020 Results on Feb 25, 2021

Intercept Pharmaceuticals, Inc. Announces Resignation of Richard Kim as President, U.S. Commercial & Strategic Marketing, Effective February 15, 2021

Intercept Pharmaceuticals, Inc. Appoints Jared M. Freedberg as General Counsel and Secretary

Rosen Law Firm Reminds Intercept Pharmaceuticals, Inc. Investors of Important January 4 Deadline in Securities Class Action

Pomerantz Law Firm Announces the Filing of a Class Action against Intercept Pharmaceuticals, Inc. and Certain Officers – ICPT

New 90-day low: €22.54

Intercept Pharmaceuticals, Inc. Announces Leadership Transition

Desglose de ingresos y gastos
Beta